To ensure that joint scientific consultations on medical devices that are conducted in parallel with the expert panel consultation have synchronised timing, the health technology developer should submit the relevant documentation for joint scientific consultation and expert panel consultation at the same time to the HTA secretariat and to the European Medicines Agency. Moreover, the JSC Subgroup or the Coordination Group and the expert panel should, within the set timetable, approve, issue and submit to the health technology developer the lists of issues, the joint scientific consultation outcome document and the advice letter.
Recital 15, Regulation (EU) 2025/117
In forcesince 24 Jan 2025